^
    Back
    Association details:
    Biomarker:BCL2 mutation
    Cancer:Follicular Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Oncol
    Title:

    Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

    Published date:
    12/06/2020
    Excerpt:
    ...141 patients were enrolled and treated with daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab...In FL and RT, genes with different mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p = 0.047) and ROS1 (0% vs. 50.0%; p = 0.044), respectively...
    DOI:
    10.1016/j.tranon.2020.100977